- Conditions
- Primary IgA Nephropathy
- Interventions
- Nefecon 16mg daily
- Drug
- Lead sponsor
- Calliditas Therapeutics AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Primary IgA Nephropathy
- Interventions
- Nefecon, Placebo oral capsule
- Drug
- Lead sponsor
- Calliditas Therapeutics AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 365 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more
- Conditions
- IgA Nephropathy
- Interventions
- TARPEYO®
- Drug
- Lead sponsor
- Calliditas Therapeutics AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Fresno, California + 30 more